Moreover, more recently, Hadoux and Elisei et al. conducted a phase 3 randomized clinical trial comparing selpercatinib as first-line therapy with the physician’s choice of cabozantinib or vandetanib (LIBRETTO-531 clinicaltrialgov NCT04211337) in patients with RET-mutant MTC [18]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.